BeiGene To Become First Tri-Listed Biotech Amid Offer Price Concerns

 
• By Dexter Jie Yan
  
Stock Exchange STAR Market
BeiGene's Shanghai IPO price draws investor concerns in China. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia